Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06082947 · ClinicalTrials.gov registry record · NA
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
A NA study of Hematologic Malignancy and Hematopoietic Stem Cell Transplantation, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06082947 is a NA study of Hematologic Malignancy and Hematopoietic Stem Cell Transplantation that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 50 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06082947, a NA study of Hematologic Malignancy and Hematopoietic Stem Cell Transplantation, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT). Patients will receive an allogenic HSCT from a matched unrelated donor (MUD), mismatch unrelated donor (MMUD) or a mismatched related (haploidentical) donor. Patients will receive a granulocyte-colony stimulating factor (G-CSF) ± Plerixafor donor mobilized peripheral stem cell donor transplant following CliniMACS® αβT cell/CD19+B cell depletion. Cluster of Differentiation 34 (CD34) and αβT cell content of the graft is determined based on the transplant indication.
Conditions Studied
Interventions
- DEVICE CliniMACS®
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-18 |
| Est. Completion | 2030-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06082947
The ClinicalTrials.gov registry entry for NCT06082947 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (78% lower). The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which CliniMACS® is the first listed.
NCT06082947 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06082947 about?
NCT06082947 is a clinical study titled "αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)". This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopo...
What is the current status of trial NCT06082947?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-12-18. Estimated completion is 2030-12-01.
What conditions does trial NCT06082947 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Hematopoietic Stem Cell Transplantation.
What interventions are being tested in trial NCT06082947?
The interventions under investigation include: CliniMACS® (DEVICE).
Who is sponsoring clinical trial NCT06082947?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06082947 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
RECRUITING · NA
-
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
RECRUITING · NA
-
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.